RGBP: Regen BioPharma, Inc. Stock

by  •  • Comments Off on RGBP: Regen BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.92
Enterprise Value ($M) 3.53
Book Value ($M) -5.18
Book Value / Share -1.24
Price / Book -0.56
NCAV ($M) -5.19
NCAV / Share -1.25
Price / NCAV -0.56

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -2.20
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.02
Current Ratio 0.02

Balance Sheet (mrq) ($M)
Current Assets 0.12
Assets 0.14
Liabilities 5.32
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.24
Operating Income -0.69
Net Income 1.16
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.17
Cash from Investing 0.00
Cash from Financing 0.24

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-24 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR
2024-01-19 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2023-11-20 10-K United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR
2023-07-25 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 1

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 300 853 35.17
2024-04-24 4,773 8,638 55.26
2024-04-23 1,433 2,632 54.45
2024-04-22 250 1,490 16.78

(click for more detail)

Similar Companies
RBSH – Rebus Holdings, Inc. RELV – Reliv' International, Inc.
REPCF – RepliCel Life Sciences Inc. RGRX – RegeneRx Biopharmaceuticals, Inc.
RGTPQ – RegenETP, Inc.


Financial data and stock pages provided by
Fintel.io